Waleed K. Alsarhani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Waleed K. Alsarhani has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Rahaf M. Al Malawi
Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
6 shared publicationsAbdulmohsen Almulhim
Department of Ophthalmology, College of Medicine, Jouf University, Sakakah, Al-Jouf, Saudi Arabia
4 shared publicationsAbdullah I. Almater
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
3 shared publications- Ahmed M. Abu El-Asrar
King Saud University
3 shared publications Abdullah Alzubaidi
Department of Ophthalmology, College of Medicine King Saud University Riyadh Saudi Arabia
2 shared publicationsBader Alqahtani
Department of Ophthalmology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
2 shared publications
Latest Publications
- 24 September 2026
- Published by Springer Nature in Eye
- Vol. 40 (16) , 2516-2525
Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis
Retinal vein occlusion (RVO) shares key pathophysiological pathways with metabolic and atherothrombotic disorders. Emerging evidence suggests that statins and antidiabetic drugs may be associated with lower RVO incidence, yet their potential to modify RVO risk remains uncertain. A systematic search of MEDLINE, Embase, Scopus, and Web of Science was performed from inception through June 11, 2025, for studies evaluating the association between systemically administered antidiabetic or lipid-lowering agents and RVO. Risk of bias was assessed using the Newcastle–Ottawa Scale. Association between antidiabetic or lipid-lowering therapy and RVO risk was the primary outcome, and drug-class-specific associations, differences by RVO subtype, and related retinal outcomes were the secondary outcomes. Certainty of evidence was appraised. Protocol registered in PROSPERO (CRD420251077729). Ten good-quality studies (six cohorts and four case–control) involving over 2 million adults met eligibility criteria. Meta-analysis results suggest that statin use consistently reduced RVO risk; pooled effect odds ratio (OR) = 0.65 (95% CI = 0.53–0.79; I² = 29%) with moderate certainty. Studies suggest metformin monotherapy halved risk [hazard ratio (HR) = 0.46, 0.30–0.73], and glucagon-like peptide-1(GLP-1) receptor agonists were associated with reduced risk compared to dipeptidyl-peptidase-4 (DPP-4) inhibitors (HR = 0.73, 0.54–0.98). Findings for sodium–glucose cotransporter-2 (SGLT-2) inhibitors were inconsistent, showing harm versus other oral glucose-lowering drugs in 1 Korean study (HR = 1.26, 1.06–1.51) but benefit versus DPP-4 inhibitors in a Taiwanese study (HR = 0.76, 0.59–0.98). Other conventional agents (repaglinide, thiazolidinediones, sulfonylureas, α-glucosidase inhibitors, insulin) yielded imprecise or null estimates. Only statins met criteria for meta-analysis; findings for other drug classes were narratively synthesised from single studies. Statins show moderate evidence of an association with reduced RVO risk. Signals of benefit for metformin and GLP-1 receptor agonists arise from single large cohorts and require independent replication. Additionally, the role of SGLT-2 inhibitors remains uncertain. These indicators warrant confirmation in prospective studies and may inform tailored retinal vascular risk reduction strategies in patients with diabetes and dyslipidaemia.
- 24 September 2026
- Published by Springer Nature in Eye
- Vol. 40 (16) , 2516-2525
Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis
Retinal vein occlusion (RVO) shares key pathophysiological pathways with metabolic and atherothrombotic disorders. Emerging evidence suggests that statins and antidiabetic drugs may be associated with lower RVO incidence, yet their potential to modify RVO risk remains uncertain. A systematic search of MEDLINE, Embase, Scopus, and Web of Science was performed from inception through June 11, 2025, for studies evaluating the association between systemically administered antidiabetic or lipid-lowering agents and RVO. Risk of bias was assessed using the Newcastle–Ottawa Scale. Association between antidiabetic or lipid-lowering therapy and RVO risk was the primary outcome, and drug-class-specific associations, differences by RVO subtype, and related retinal outcomes were the secondary outcomes. Certainty of evidence was appraised. Protocol registered in PROSPERO (CRD420251077729). Ten good-quality studies (six cohorts and four case–control) involving over 2 million adults met eligibility criteria. Meta-analysis results suggest that statin use consistently reduced RVO risk; pooled effect odds ratio (OR) = 0.65 (95% CI = 0.53–0.79; I² = 29%) with moderate certainty. Studies suggest metformin monotherapy halved risk [hazard ratio (HR) = 0.46, 0.30–0.73], and glucagon-like peptide-1(GLP-1) receptor agonists were associated with reduced risk compared to dipeptidyl-peptidase-4 (DPP-4) inhibitors (HR = 0.73, 0.54–0.98). Findings for sodium–glucose cotransporter-2 (SGLT-2) inhibitors were inconsistent, showing harm versus other oral glucose-lowering drugs in 1 Korean study (HR = 1.26, 1.06–1.51) but benefit versus DPP-4 inhibitors in a Taiwanese study (HR = 0.76, 0.59–0.98). Other conventional agents (repaglinide, thiazolidinediones, sulfonylureas, α-glucosidase inhibitors, insulin) yielded imprecise or null estimates. Only statins met criteria for meta-analysis; findings for other drug classes were narratively synthesised from single studies. Statins show moderate evidence of an association with reduced RVO risk. Signals of benefit for metformin and GLP-1 receptor agonists arise from single large cohorts and require independent replication. Additionally, the role of SGLT-2 inhibitors remains uncertain. These indicators warrant confirmation in prospective studies and may inform tailored retinal vascular risk reduction strategies in patients with diabetes and dyslipidaemia.
- Retraction
- 17 July 2026
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (10) , 1209
Monkeypox-Associated Disciform Keratitis: Retraction
Was not provided for this article.
- 17 July 2026
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (10) , 1209
RetractionMonkeypox-Associated Disciform Keratitis: Retraction
Was not provided for this article.
- Open Access
- 6 May 2026
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 30 (3) , 104853
Characteristic ocular features of pediatric patients with Loeys-Dietz syndrome
- 6 May 2026
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 30 (3) , 104853
Open AccessCharacteristic ocular features of pediatric patients with Loeys-Dietz syndrome
- Open Access
- 16 February 2026
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (4) , 790-804
Comparative safety and efficacy of brinzolamide/timolol and dorzolamide/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis
Purpose: This systematic review and meta-analysis aims to compare BT and DT in terms of intraocular pressure (IOP) reduction, safety, and patient preferences. Methods: Following PRISMA and Cochrane guidelines, we searched PubMed, Scopus, Web of Science, CENTRAL, and Embase up to December 30, 2024. Twelve studies (11 randomized controlled trials [RCTs]) involving 1,885 patients were included. Primary outcomes were IOP reduction and adverse events. Statistical analyses were performed using Review Manager 5.4.1, with mean differences (MD) and risk ratios (RR) calculated for continuous and binary outcomes. Results: BT demonstrated a statistically greater reduction in the morning IOP compared to DT at 12 weeks or more (BT: MD = 0.56 mmHg, P < 0.001; BTFC subgroup: MD = 0.66, P < 0.001), with consistent benefits observed at 8 and 4 weeks. No significant difference was observed in the evening IOP reduction. BT combination was associated with a 49% lower risk of eye irritation (RR = 0.51, P < 0.001) but a threefold higher risk of blurred vision (RR = 3.14, P < 0.001). Patient preference studies favored brinzolamide/timolol fixed combination (BTFC) due to reduced ocular discomfort. Conclusion: BT showed a statistically greater reduction in morning IOP than DT; however, the absolute difference was modest, and its clinical relevance is uncertain. BT was associated with less ocular irritation but higher blurred vision risk. High heterogeneity for evening IOP and overall adverse events limits interpretation. Considering these findings, the choice of treatment usually depends on the patient's tolerance to higher initial ocular irritation in DT or blurring of vision in BT. Longer-term trials with 24-h IOP and preference are needed to assess these outcomes meaningfully.
- 16 February 2026
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (4) , 790-804
Open AccessComparative safety and efficacy of brinzolamide/timolol and dorzolamide/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis
Purpose: This systematic review and meta-analysis aims to compare BT and DT in terms of intraocular pressure (IOP) reduction, safety, and patient preferences. Methods: Following PRISMA and Cochrane guidelines, we searched PubMed, Scopus, Web of Science, CENTRAL, and Embase up to December 30, 2024. Twelve studies (11 randomized controlled trials [RCTs]) involving 1,885 patients were included. Primary outcomes were IOP reduction and adverse events. Statistical analyses were performed using Review Manager 5.4.1, with mean differences (MD) and risk ratios (RR) calculated for continuous and binary outcomes. Results: BT demonstrated a statistically greater reduction in the morning IOP compared to DT at 12 weeks or more (BT: MD = 0.56 mmHg, P < 0.001; BTFC subgroup: MD = 0.66, P < 0.001), with consistent benefits observed at 8 and 4 weeks. No significant difference was observed in the evening IOP reduction. BT combination was associated with a 49% lower risk of eye irritation (RR = 0.51, P < 0.001) but a threefold higher risk of blurred vision (RR = 3.14, P < 0.001). Patient preference studies favored brinzolamide/timolol fixed combination (BTFC) due to reduced ocular discomfort. Conclusion: BT showed a statistically greater reduction in morning IOP than DT; however, the absolute difference was modest, and its clinical relevance is uncertain. BT was associated with less ocular irritation but higher blurred vision risk. High heterogeneity for evening IOP and overall adverse events limits interpretation. Considering these findings, the choice of treatment usually depends on the patient's tolerance to higher initial ocular irritation in DT or blurring of vision in BT. Longer-term trials with 24-h IOP and preference are needed to assess these outcomes meaningfully.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Saudi Journal of Ophthalmology
- Vol. 40 (1) , 105
Re: A response to: Letter to the editor regarding research productivity of ophthalmology residents in Saudi Arabia: A comprehensive analysis
- 1 January 2026
- Published by Wolters Kluwer Health in Saudi Journal of Ophthalmology
- Vol. 40 (1) , 105
Open AccessRe: A response to: Letter to the editor regarding research productivity of ophthalmology residents in Saudi Arabia: A comprehensive analysis
- Open Access
- 9 July 2025
- Published by Wolters Kluwer Health in Saudi Journal of Ophthalmology
- Vol. 40 (1) , 37-41
Research productivity of ophthalmology residents in Saudi Arabia: A comprehensive analysis
PURPOSE: The purpose of the study was to assess the research productivity of ophthalmology residents in Saudi Arabia and identify factors associated with significant research output. METHODS: This is a cross-sectional study of ophthalmology training programs across Saudi Arabia from 2015 to 2019. RESULTS: The study included 225 ophthalmology residents, with a mean number of publications of 3.25 ± 4.59 and an average h-index of 1.20 ± 1.38. Statistically significant differences were observed between training programs in the mean number of publications ( P < 0.001), h-index ( P < 0.001), and citations ( P < 0.001). The programs with the highest mean publication counts were King Saud University (8.03 ± 8.00), King Khaled Eye Specialist Hospital (3.80 ± 3.87), and the Eastern program (3.07 ± 4.04). Residents pursuing subspecialty fellowships, particularly in oculoplastic surgery and cornea, exhibited higher research output. Furthermore, the mean number of publications ( P < 0.001), citations ( P < 0.001), and h-index ( P < 0.001) were associated with attaining future academic positions. Pursuing fellowship was significantly linked to the number of publications ( P = 0.009) and h-index ( P = 0.012). CONCLUSION: This study underscores the variability in research productivity among ophthalmology residents and highlights the influence of training programs, fellowship ambitions, and academic aspirations on research output.
- 9 July 2025
- Published by Wolters Kluwer Health in Saudi Journal of Ophthalmology
- Vol. 40 (1) , 37-41
Open AccessResearch productivity of ophthalmology residents in Saudi Arabia: A comprehensive analysis
PURPOSE: The purpose of the study was to assess the research productivity of ophthalmology residents in Saudi Arabia and identify factors associated with significant research output. METHODS: This is a cross-sectional study of ophthalmology training programs across Saudi Arabia from 2015 to 2019. RESULTS: The study included 225 ophthalmology residents, with a mean number of publications of 3.25 ± 4.59 and an average h-index of 1.20 ± 1.38. Statistically significant differences were observed between training programs in the mean number of publications ( P < 0.001), h-index ( P < 0.001), and citations ( P < 0.001). The programs with the highest mean publication counts were King Saud University (8.03 ± 8.00), King Khaled Eye Specialist Hospital (3.80 ± 3.87), and the Eastern program (3.07 ± 4.04). Residents pursuing subspecialty fellowships, particularly in oculoplastic surgery and cornea, exhibited higher research output. Furthermore, the mean number of publications ( P < 0.001), citations ( P < 0.001), and h-index ( P < 0.001) were associated with attaining future academic positions. Pursuing fellowship was significantly linked to the number of publications ( P = 0.009) and h-index ( P = 0.012). CONCLUSION: This study underscores the variability in research productivity among ophthalmology residents and highlights the influence of training programs, fellowship ambitions, and academic aspirations on research output.
- Open Access
- 15 May 2025
- Published by Elsevier in AJO International
- Vol. 2 (2)
Povidone-iodine in the treatment of infectious keratitis: A systematic review
- 15 May 2025
- Published by Elsevier in AJO International
- Vol. 2 (2)
Open AccessPovidone-iodine in the treatment of infectious keratitis: A systematic review
- Open Access
- 19 February 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (4) , e572-e577
Educational background, professional experience, and research productivity of Canada's academic ophthalmology leadership
- 19 February 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (4) , e572-e577
Open AccessEducational background, professional experience, and research productivity of Canada's academic ophthalmology leadership
- 30 January 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 103 (4) , 380-387
Effect of panretinal photocoagulation on retinal oxygen metabolism and ocular blood flow in diabetic retinopathy
Purpose: To investigate the effects of panretinal photocoagulation (PRP) on retinal oxygen metabolism, calibre of retinal vessels, and blood flow velocity in the optic nerve head (ONH) and choroid in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR).Methods: In this retrospective study, 37 patients (37 eyes) were studied. Retinal oximetry and laser speckle flowgraphy measurements were performed at baseline and after PRP.Results: After PRP, oxygen saturation of retinal arterioles (p = 0.003) and arteriovenous oxygen saturation difference (p = 0.005) significantly increased. On the other hand, the calibre of retinal arterioles significantly decreased (p = 0.016). In the ONH, mean blur rate (MBR)‐vessel (p = 0.002), representing blood flow velocity in the retinal vessels, and MBR‐tissue (p = 0.002), representing ONH blood flow velocity, and choroidal MBR (p = 0.012) significantly decreased. At baseline, there were significant negative correlations between ONH MBR‐overall (r = −0.382, p = 0.026) and ONH MBR‐tissue (r = −0.455, p = 0.007) and arteriovenous oxygen saturation difference. After PRP, choroidal MBR had a significant negative correlation with arteriolar oxygen saturation (r = −0.415, p = 0.016).Conclusions: The effects of PRP are correlated with increased arteriovenous oxygen saturation difference, reduction in the calibre of retinal arterioles, and reduction of retinal and choroidal blood flow velocities.
- 30 January 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 103 (4) , 380-387
Effect of panretinal photocoagulation on retinal oxygen metabolism and ocular blood flow in diabetic retinopathy
Purpose: To investigate the effects of panretinal photocoagulation (PRP) on retinal oxygen metabolism, calibre of retinal vessels, and blood flow velocity in the optic nerve head (ONH) and choroid in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR).Methods: In this retrospective study, 37 patients (37 eyes) were studied. Retinal oximetry and laser speckle flowgraphy measurements were performed at baseline and after PRP.Results: After PRP, oxygen saturation of retinal arterioles (p = 0.003) and arteriovenous oxygen saturation difference (p = 0.005) significantly increased. On the other hand, the calibre of retinal arterioles significantly decreased (p = 0.016). In the ONH, mean blur rate (MBR)‐vessel (p = 0.002), representing blood flow velocity in the retinal vessels, and MBR‐tissue (p = 0.002), representing ONH blood flow velocity, and choroidal MBR (p = 0.012) significantly decreased. At baseline, there were significant negative correlations between ONH MBR‐overall (r = −0.382, p = 0.026) and ONH MBR‐tissue (r = −0.455, p = 0.007) and arteriovenous oxygen saturation difference. After PRP, choroidal MBR had a significant negative correlation with arteriolar oxygen saturation (r = −0.415, p = 0.016).Conclusions: The effects of PRP are correlated with increased arteriovenous oxygen saturation difference, reduction in the calibre of retinal arterioles, and reduction of retinal and choroidal blood flow velocities.
- Open Access
- 12 August 2024
- Published by Springer Nature in BMC Ophthalmology
- Vol. 24 (1) , 1-7
Outcomes of sutured scleral-fixated intraocular lens implantation combined with penetrating keratoplasty
Background: The purpose of the study was to assess visual outcomes, complications, intraocular lens (IOL) stability, and corneal status after sutured scleral-fixated intraocular lens implantation combined with penetrating keratoplasty (PKP). Methods: This retrospective single-arm cohort study included patients who underwent PKP and sutured scleral-fixated intraocular lens implantation between 2013 and 2018 at the Dhahran Eye Specialty Hospital. The eyes were examined postoperatively at 1, 3, 6, 12, and 24 months. Corneal status, complications, and IOL status were also evaluated periodically, and the number of eyes with a BCVA of > 20/200 was recorded. Results: Twenty-two eyes from 22 patients were included. The median duration of follow-up was 3 (IQR 1.8; 4.4) years. Reasons for surgery were traumatic globe rupture (six eyes, 27.3%), bullous keratopathy (nine eyes, 40.1%), failed previous graft (five eyes, 22.7%), and corneal scarring (two eyes, 9.1%). Twelve (54.5%) eyes showed a BCVA of > 20/200 (non-blind) at 12 months after surgery and only five (22.7%) before surgery. Twelve months after surgery, 13 patients showed an improvement in BCVA in two lines (59.1%), seven remained the same (31.8%), and 2 deteriorated (9.1%). The indication for surgery (p = 0.2) and the stability of the sutured-scleral fixated IOL (p = 0.8) were not associated with an improvement in BCVA at the final follow-up. The corneal graft remained clear in nine eyes (40.9%) at a median duration of 3 years. The overall average survival period for all corneal grafts was 42.9 months. Conclusions: The combination of sutured scleral-fixated intraocular lens implants and PKP is an effective intervention for preserving visual acuity in patients with complex cases. However, the risk of graft failure and then need for repeat transplantation should be taken into consideration.
- 12 August 2024
- Published by Springer Nature in BMC Ophthalmology
- Vol. 24 (1) , 1-7
Open AccessOutcomes of sutured scleral-fixated intraocular lens implantation combined with penetrating keratoplasty
Background: The purpose of the study was to assess visual outcomes, complications, intraocular lens (IOL) stability, and corneal status after sutured scleral-fixated intraocular lens implantation combined with penetrating keratoplasty (PKP). Methods: This retrospective single-arm cohort study included patients who underwent PKP and sutured scleral-fixated intraocular lens implantation between 2013 and 2018 at the Dhahran Eye Specialty Hospital. The eyes were examined postoperatively at 1, 3, 6, 12, and 24 months. Corneal status, complications, and IOL status were also evaluated periodically, and the number of eyes with a BCVA of > 20/200 was recorded. Results: Twenty-two eyes from 22 patients were included. The median duration of follow-up was 3 (IQR 1.8; 4.4) years. Reasons for surgery were traumatic globe rupture (six eyes, 27.3%), bullous keratopathy (nine eyes, 40.1%), failed previous graft (five eyes, 22.7%), and corneal scarring (two eyes, 9.1%). Twelve (54.5%) eyes showed a BCVA of > 20/200 (non-blind) at 12 months after surgery and only five (22.7%) before surgery. Twelve months after surgery, 13 patients showed an improvement in BCVA in two lines (59.1%), seven remained the same (31.8%), and 2 deteriorated (9.1%). The indication for surgery (p = 0.2) and the stability of the sutured-scleral fixated IOL (p = 0.8) were not associated with an improvement in BCVA at the final follow-up. The corneal graft remained clear in nine eyes (40.9%) at a median duration of 3 years. The overall average survival period for all corneal grafts was 42.9 months. Conclusions: The combination of sutured scleral-fixated intraocular lens implants and PKP is an effective intervention for preserving visual acuity in patients with complex cases. However, the risk of graft failure and then need for repeat transplantation should be taken into consideration.